Latest News

Stay up-to-date on the latest developments in the fields of vitreo-retinal disease treatments and ophthalmology in general. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with ThromboGenics associates. Be sure to check in regularly for the latest ThromboGenics’ press releases or just subscribe to our mailing list to receive regular updates.

Haven’t found what you’re looking for? Take a look at our press release history.

 

 

  • 16 Mar 2017
    ThromboGenics Business Update – FY 2016
  • 29 Jan 2017
    Regulated Information - Transparency Statement
  • 17 Jan 2017
    ONCURIOUS NV Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma
  • 10 Jan 2017
    ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME)
  • 23 Dec 2016
    ThromboGenics Announces Protocol Amendment to Phase II CIRCLE Trial Evaluating THR-409 (ocriplasmin) in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)
  • 9 Dec 2016
    ThromboGenics Announces Financial Calendar 2017
  • 20 Oct 2016
    ThromboGenics Business Update – Q3 2016
  • 11 Oct 2016
    ThromboGenics’ Clinical Data to be Presented at 2016 AAO Meeting in Chicago
  • 5 Oct 2016
    ThromboGenics Presenting New Research Findings at the European Association for Vision and Eye Research (EVER) Congress in Nice
  • 7 Sep 2016
    ThromboGenics Presenting New Ophthalmic Research Data at 16th EURETINA Congress in Copenhagen
  • 25 Aug 2016
    ThromboGenics Business Update – H1 2016
  • 8 Aug 2016
    ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology, Journal of the American Academy of Ophthalmology (AAO)
  • 3 Aug 2016
    ThromboGenics Presenting Ocriplasmin Research Findings at Upcoming ASRS 2016 Annual Scientific Meeting in San Francisco
  • 8 Jun 2016
    ThromboGenics Receives US FDA Approval for New ‘Already-Diluted’ Formulation of JETREA®
  • 7 Jun 2016
    ThromboGenics Highlights Diabetic Eye Drug Developments at ADA’s 76th Scientific Sessions Meeting in New Orleans